Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide.

Pulmonary delivery of messenger RNA (mRNA) has considerable potential as therapy or vaccine for a range of lung diseases. Inhaled dry powder formulation of mRNA is particularly attractive as it has superior stability and dry powder inhaler is relatively easy to use. A safe and effective mRNA delivery vector as well as a suitable particle engineering method are required to produce a dry powder formulation that is respirable and mediates robust transfection in the lung. Here, we introduce a novel RNA delivery vector, PEG12KL4, in which the synthetic cationic KL4 peptide is attached to a monodisperse linear PEG of 12-mers. The PEG12KL4 formed nano-sized complexes with mRNA at 10:1 ratio (w/w) and mediated effective transfection on human lung epithelial cells. PEG12KL4/mRNA complexes were successfully formulated into dry powder by spray drying (SD) and spray freeze drying (SFD) techniques. Both SD and SFD powder exhibited satisfactory aerosol properties for inhalation. More importantly, the biological activity of the PEG12KL4 /mRNA complexes were successfully preserved after drying. Using luciferase mRNA, the intratracheal administration of the liquid or powder aerosol of PEG12KL4 /mRNA complexes at a dose of 5 µg mRNA resulted in luciferase expression in the deep lung region of mice 24 h post-transfection. The transfection efficiency was superior to naked mRNA or lipoplexes (Lipofectamine 2000), in which luciferase expression was weaker and restricted to the tracheal region only. There was no sign of inflammatory response or toxicity of the PEG12KL4 /mRNA complexes after single intratracheal administration. Overall, PEG12KL4 is an excellent mRNA transfection agent for pulmonary delivery. This is also the first study that successfully demonstrates the preparation of inhalable dry powder mRNA formulations with in vivo transfection efficiency, showing the great promise of PEG12KL4 peptide as a mRNA delivery vector candidate for clinical applications.

[1]  Steven J. Shire,et al.  Protein Inhalation Powders: Spray Drying vs Spray Freeze Drying , 1999, Pharmaceutical Research.

[2]  Michael Y. T. Chow,et al.  Inhaled powder formulation of naked siRNA using spray drying technology with l-leucine as dispersion enhancer. , 2017, International journal of pharmaceutics.

[3]  Özlem Türeci,et al.  mRNA-based therapeutics — developing a new class of drugs , 2014, Nature Reviews Drug Discovery.

[4]  M. Idzko,et al.  Modified Foxp3 mRNA protects against asthma through an IL-10-dependent mechanism. , 2013, The Journal of clinical investigation.

[5]  S. Koch,et al.  Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer , 2014, BMC Cancer.

[6]  Baolin Liu,et al.  Freeze-drying of proteins. , 2015, Methods in molecular biology.

[7]  J. Mak,et al.  From Pulmonary Surfactant, Synthetic KL4 Peptide as Effective siRNA Delivery Vector for Pulmonary Delivery. , 2017, Molecular pharmaceutics.

[8]  W. Wong,et al.  Receptor-Interacting Protein 2 Gene Silencing Attenuates Allergic Airway Inflammation , 2013, The Journal of Immunology.

[9]  P. Alam.  ‘E’ , 2021, Composites Engineering: An A–Z Guide.

[10]  Michael Y. T. Chow,et al.  Porous and highly dispersible voriconazole dry powders produced by spray freeze drying for pulmonary delivery with efficient lung deposition , 2019, International journal of pharmaceutics.

[11]  Samuel K Lai,et al.  PEGylation for enhancing nanoparticle diffusion in mucus☆ , 2017, Advanced drug delivery reviews.

[12]  N. Pedemonte,et al.  Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis , 2018, Scientific Reports.

[13]  Kimberly J. Hassett,et al.  Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  J. Rosenecker,et al.  Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems , 2017, Gene Therapy.

[15]  G. Acsadi,et al.  Direct gene transfer into mouse muscle in vivo. , 1990, Science.

[16]  A. Bohr,et al.  Inhalable siRNA‐loaded nano‐embedded microparticles engineered using microfluidics and spray drying , 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[17]  I. Sahu,et al.  Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  Establishment of an Evaluation Method for Gene Silencing by Serial Pulmonary Administration of siRNA and pDNA Powders: Naked siRNA Inhalation Powder Suppresses Luciferase Gene Expression in the Lung. , 2019, Journal of pharmaceutical sciences.

[19]  Gregg A. Duncan,et al.  PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[20]  M. Hindle,et al.  Characterization of a New High-Dose Dry Powder Inhaler (DPI) Based on a Fluidized Bed Design , 2015, Annals of Biomedical Engineering.

[21]  Kevin Braeckmans,et al.  Extracellular barriers in respiratory gene therapy☆ , 2008, Advanced Drug Delivery Reviews.

[22]  Dominique N. Price,et al.  Challenges Associated with the Pulmonary Delivery of Therapeutic Dry Powders for Preclinical Testing , 2019, KONA Powder and Particle Journal.

[23]  J. Rosenecker,et al.  Nebulisation of IVT mRNA Complexes for Intrapulmonary Administration , 2015, PloS one.

[24]  Hak-Kim Chan,et al.  Dry powder aerosol delivery systems: current and future research directions. , 2006, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[25]  J. Rosenecker,et al.  Expression of therapeutic proteins after delivery of chemically modified mRNA in mice , 2011, Nature Biotechnology.

[26]  Y. Nakanishi,et al.  Small interfering RNA against CD86 during allergen challenge blocks experimental allergic asthma , 2014, Respiratory Research.

[27]  R. Malcolmson,et al.  Dry powder formulations for pulmonary delivery , 1998 .

[28]  K. Kataoka,et al.  Screening of mRNA Chemical Modification to Maximize Protein Expression with Reduced Immunogenicity , 2015, Pharmaceutics.

[29]  Michael Y. T. Chow,et al.  Using two‐fluid nozzle for spray freeze drying to produce porous powder formulation of naked siRNA for inhalation , 2018, International journal of pharmaceutics.

[30]  T. Okuda,et al.  Development of spray‐freeze‐dried siRNA/PEI powder for inhalation with high aerosol performance and strong pulmonary gene silencing activity , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[31]  H. Iwamoto,et al.  Intratracheal Administration of siRNA Dry Powder Targeting Vascular Endothelial Growth Factor Inhibits Lung Tumor Growth in Mice , 2018, Molecular therapy. Nucleic acids.

[32]  S. Sekulic.  [Pulmonary surfactant]. , 1974, Plucne bolesti i tuberkuloza.

[33]  Jolyon P. Mitchell,et al.  Particle Size Analysis of Aerosols from Medicinal Inhalers , 2004 .

[34]  J. Hanes,et al.  Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. , 2009, Advanced drug delivery reviews.

[35]  K. Kinbara.  Monodisperse engineered PEGs for bio-related applications , 2018, Polymer Journal.

[36]  J. Rantanen,et al.  Effect of thermal and shear stresses in the spray drying process on the stability of siRNA dry powders. , 2019, International journal of pharmaceutics.

[37]  Robert Langer,et al.  Inhaled Nanoformulated mRNA Polyplexes for Protein Production in Lung Epithelium , 2019, Advanced materials.

[38]  U. Şahin,et al.  Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. , 2006, Blood.

[39]  Ranjita Shegokar,et al.  Polyethylene glycol (PEG): a versatile polymer for pharmaceutical applications , 2016, Expert opinion on drug delivery.

[40]  Gaurav Sahay,et al.  Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[41]  S. D. De Smedt,et al.  mRNA as gene therapeutic: how to control protein expression. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[42]  F. Bloom,et al.  Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA. , 1992, Science.

[43]  R. Subramanian,et al.  SERPINA1 mRNA as a Treatment for Alpha-1 Antitrypsin Deficiency , 2018, Journal of nucleic acids.

[44]  J. Lam,et al.  Dry Powder Formulation of Plasmid DNA and siRNA for Inhalation. , 2015, Current pharmaceutical design.